CPRX (Catalyst Pharmaceuticals) Net Income (Discontinued Operations): $0.0 Mil (TTM As of Mar. 2026)


CPRX Catalyst Pharmaceuticals Inc CPRX
92 GF Score
Price $31.40
GF Value $24.60
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Catalyst Pharmaceuticals Net Income (Discontinued Operations)?

Catalyst Pharmaceuticals CPRX 92 Net Income (Discontinued Operations) is $0.0 Mil as of Mar. 2026. GuruFocus rates CPRX with a GF Score™ of 92/100 and a GF Value™ of $24.60 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Net Income (Discontinued Operations) indicates the net income that a firm brought in from operations that will not be used in future reporting periods. Catalyst Pharmaceuticals's Net Income (Discontinued Operations) for the three months ended in Mar. 2026 was $0.0 Mil. Its Net Income (Discontinued Operations) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.0 Mil.

Catalyst Pharmaceuticals Net Income (Discontinued Operations) Related Terms

Catalyst Pharmaceuticals Net Income (Discontinued Operations) Historical Data

* Premium members only.

The historical data trend for Catalyst Pharmaceuticals's Net Income (Discontinued Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Catalyst Pharmaceuticals Net Income (Discontinued Operations) Chart

Catalyst Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income (Discontinued Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Catalyst Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Income (Discontinued Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CPRX
92GF Score
Catalyst Pharmaceuticals Inc CPRX
Net Income (Discontinued Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Catalyst Pharmaceuticals Net Income (Discontinued Operations) Calculation

Net Income (Discontinued Operations) indicates the net income that a firm brought in from operations that will not be used in future reporting periods.

Net Income (Discontinued Operations) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Discontinued Operations) of $0.0 Mil mean?
Catalyst Pharmaceuticals (CPRX) has a Net Income (Discontinued Operations) of $0.0 Mil as of Mar. 2026. Net Income (Discontinued operations) is the total net earnings from ceased operations. View historical data on Catalyst Pharmaceuticals and its competitors.
Is Catalyst Pharmaceuticals' Net Income (Discontinued Operations) too high?
Catalyst Pharmaceuticals' current Net Income (Discontinued Operations) is $0.0 Mil. Overall, Catalyst Pharmaceuticals has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Catalyst Pharmaceuticals' Net Income (Discontinued Operations) compare to VKTX and CRNX?
Catalyst Pharmaceuticals' Net Income (Discontinued Operations) of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Discontinued Operations) for a Biotechnology company?
A good Net Income (Discontinued Operations) depends on the Biotechnology industry context. However, Net Income (Discontinued Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Discontinued Operations) mean?
A high Net Income (Discontinued Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Discontinued operations) is the total net earnings from ceased operations. View historical data on Catalyst Pharmaceuticals and its competitors. Catalyst Pharmaceuticals's current Net Income (Discontinued Operations) is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Catalyst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals (CPRX) is currently considered Modestly Overvalued. The stock's GF Value™ is $24.60, compared to a current price of $31.40 — trading 27.6% above its estimated fair value. The current Net Income (Discontinued Operations) is $0.0 Mil. Catalyst Pharmaceuticals' overall GF Score™ is 92/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Discontinued Operations) calculated?
Net Income (Discontinued Operations) is calculated from a company's financial statements. For Catalyst Pharmaceuticals (CPRX), the current Net Income (Discontinued Operations) is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Catalyst Pharmaceuticals (CPRX) Overvalued in 2026?

Based on GuruFocus' analysis, Catalyst Pharmaceuticals stock appears to be overvalued. The current stock price of $31.40 is trading 27.6% above its estimated GF Value™ of $24.60. GuruFocus considers Catalyst Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for CPRX:

  • Net Income (Discontinued Operations): $0.0 Mil
  • GF Value™: $24.60 vs. price of $31.40 (27.6% above fair value)
  • GF Score™: 92/100 with 6 warning signs

No single metric tells the full story. See the CPRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Catalyst Pharmaceuticals Business Description

Other Exchanges CN2:Germany
Address 355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
92GF Score

Get the complete analysis for CPRX

Net Income (Discontinued Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.40
Price
$24.60
GF Value